​

Apellis Pharmaceuticals (APLS) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

APLS Stock Forecast

Apellis Pharmaceuticals (APLS) stock forecast, based on 25 Wall Street analysts, predicts a 12-month average price target of $35.38, with a high of $52.00 and a low of $19.00. This represents a -13.60% decline from the last price of $40.95.

$15 $25 $35 $45 $55 $65 High: $52 Avg: $35.38 Low: $19 Last Closed Price: $40.95

APLS Stock Rating

Apellis Pharmaceuticals stock's rating consensus is Buy, based on 25 Wall Street analysts. The breakdown includes 1 Strong Buy (4.00%), 17 Buy (68.00%), 6 Hold (24.00%), 1 Sell (4.00%), and 0 Strong Sell (0.00%).

Buy
Total 25 1 6 17 1 Strong Sell Sell Hold Buy Strong Buy

APLS Price Target Upside V Benchmarks

TypeNameUpside
StockApellis Pharmaceuticals-13.60%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts1113
Avg Price Target$41.00$41.00$31.15
Last Closing Price$40.95$40.95$40.95
Upside/Downside0.12%0.12%-23.93%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 26-416--20
Mar, 2631171-22
Feb, 2631171-22
Jan, 2631071-21
Dec, 2531071-21
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Apr 17, 2026Wells Fargo$41.00$40.870.32%0.12%
Jan 27, 2026Barclays$24.00$21.8110.04%-41.39%
Jan 20, 2026Wells Fargo$26.00$19.9430.39%-36.51%
Jan 13, 2026Cantor Fitzgerald$35.00$23.2050.86%-14.53%
Jan 12, 2026Goldman Sachs$19.00$23.20-18.10%-53.60%
Dec 19, 2025Stifel Nicolaus$48.00$24.4896.08%17.22%
Nov 03, 2025Graig SuvannavejhMizuho Securities$19.00$21.47-11.50%-53.60%
Oct 31, 2025Robert W. Baird$52.00$20.73150.84%26.98%
Oct 31, 2025H.C. Wainwright$45.00$20.73117.08%9.89%
Oct 29, 2025Mizuho Securities$24.00$29.70-19.19%-41.39%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 21, 2026Bank of America SecuritiesBuyBuyupgrade
Jan 12, 2026Goldman SachsSellSellhold
Dec 15, 2025William BlairOutperformOutperformhold
Nov 05, 2025Wolfe ResearchPeer Performinitialise
Oct 21, 2025H.C. WainwrightBuyBuyhold
Oct 15, 2025Wells FargoSector PerformOverweightupgrade
Sep 26, 2025Goldman SachsBuySelldowngrade
Jul 30, 2025ScotiabankSector PerformSector Performhold
Jan 07, 2025RBC CapitalSector PerformSector Performhold
Nov 05, 2024Bank of America SecuritiesBuyBuyhold

Financial Forecast

EPS Forecast

$-15 $-9 $-3 $3 $9 $15 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-8.84$-6.15$-4.45$-1.60----
Avg Forecast$-8.70$-6.27$-4.48$-1.66$-0.90$0.63$1.08$2.37
High Forecast$-7.89$-5.68$-3.86$-1.56$0.07$10.66$2.81$2.93
Low Forecast$-10.21$-7.37$-5.06$-1.88$-1.45$-2.05$-0.10$1.99
Surprise %1.61%-1.91%-0.67%-3.61%----

Revenue Forecast

$0 $400M $800M $1B $2B $2B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$66.56M$75.42M$396.59M$781.37M$689.38M---
Avg Forecast$15.01M$76.64M$390.75M$766.78M$857.55M$1.08B$1.21B$1.46B
High Forecast$17.00M$87.04M$396.54M$782.30M$1.02B$1.08B$1.22B$1.72B
Low Forecast$13.93M$71.17M$386.55M$755.57M$777.37M$1.08B$1.21B$1.28B
Surprise %343.56%-1.59%1.49%1.90%-19.61%---

Net Income Forecast

$-1B $-500M $0 $500M $1B $2B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-746.35M$-652.17M$-528.63M$-197.88M$22.39M---
Avg Forecast$-488.72M$-578.22M$-528.63M$-204.51M$-134.94M$-11.88M$156.49M$281.76M
High Forecast$-390.98M$-462.58M$-422.90M$-185.39M$7.85M$1.26B$333.91M$348.22M
Low Forecast$-586.47M$-693.87M$-634.35M$-223.62M$-171.76M$-242.72M$-12.24M$236.38M
Surprise %52.71%12.79%--3.24%-116.59%---

APLS Forecast FAQ

Is Apellis Pharmaceuticals stock a buy?

Apellis Pharmaceuticals stock has a consensus rating of Buy, based on 25 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 17 Buy, 6 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Apellis Pharmaceuticals is a favorable investment for most analysts.

What is Apellis Pharmaceuticals's price target?

Apellis Pharmaceuticals's price target, set by 25 Wall Street analysts, averages $35.38 over the next 12 months. The price target range spans from $19 at the low end to $52 at the high end, suggesting a potential -13.60% change from the previous closing price of $40.95.

How does Apellis Pharmaceuticals stock forecast compare to its benchmarks?

Apellis Pharmaceuticals's stock forecast shows a -13.60% downside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Apellis Pharmaceuticals over the past three months?

  • April 2026: 0% Strong Buy, 20.00% Buy, 80.00% Hold, 0% Sell, 0% Strong Sell.
  • March 2026: 13.64% Strong Buy, 50.00% Buy, 31.82% Hold, 4.55% Sell, 0% Strong Sell.
  • February 2026: 13.64% Strong Buy, 50.00% Buy, 31.82% Hold, 4.55% Sell, 0% Strong Sell.

What is Apellis Pharmaceuticals’s EPS forecast?

Apellis Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2026 is $0.63, marking a 0% decrease from the reported $0 in 2025. Estimates for the following years are $1.08 in 2027, and $2.37 in 2028.

What is Apellis Pharmaceuticals’s revenue forecast?

Apellis Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2026 is $1.08B, reflecting a 56.53% increase from the reported $689.38M in 2025. The forecast for 2027 is $1.21B, and $1.46B for 2028.

What is Apellis Pharmaceuticals’s net income forecast?

Apellis Pharmaceuticals's net income forecast for the fiscal year ending in December 2026 stands at $-11.883M, representing a -153.08% decrease from the reported $22.39M in 2025. Projections indicate $156.49M in 2027, and $281.76M in 2028.